Hua Medicine (Shanghai) Ltd. (SEHK: 2552)
Health Care · Pharmaceuticals · CN
HK$2.60
-1.14% today · -25.9% 1Y
Hua Medicine (Shanghai) Ltd. (SEHK: 2552) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $330.48M and employs 328 people.
Over the last twelve months the share price has lost 25.9%, trading between 1.97 and 4.95.
Tweenvest scores Hua Medicine (Shanghai) Ltd. across four factors: quality 52/100, value 72/100. Its strongest factor is value.
2552 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $330.48M
- Revenue (TTM)
- $96.34M
- P/E
- —
- EPS
- -0.11
- Dividend yield
- —
- Beta (5Y)
- 0.80
- 52-week high
- HK$4.95
- 52-week low
- HK$1.97
- Avg volume (3M)
- —
- Shares outstanding
- 996.52M
- Employees
- 328
- Next earnings
- —
About Hua Medicine (Shanghai) Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
- ISIN
- KYG4644K1022
- Founded
- 2011
- Listed since
- Sep 14, 2018
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,251.95 | +0.40% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.12 | +0.03% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $155.00 | +2.88% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.42 | +1.61% |
Figures last refreshed Aug 18, 2026.